News
Adcendo ApS Announces Extension of Series A Financing to 82M EUR to Ensure Broad Development of its First-in-class ADC Pipeline
Series A Financing extension led by Pontifax Venture Capital…
Novo Nordisk Foundation to support crucial education of health professionals in India and East Africa with up to DKK 1bn (USD 140m)
The global shortage of qualified health professionals is an increasing…
Sequana Medical announces submission of Investigational New Drug (IND) application for DSR® 2.0 for treatment of congestive heart failure
Ghent, Belgium – 03 April 2023 – Sequana Medical NV (Euronext…
Granular Therapeutics to accelerate development of next-generation pipeline for treating mast cell driven diseases
Clinical candidate selection finalised for lead programme targeting…
Poolbeg Pharma Plc: Results for the year ended 31 December 2022
Significant milestones reached, well capitalised and positioned…
iOnctura Awarded UK’s MHRA Innovation Passport For Entry Into Innovative Licensing And Access Pathway (ILAP)
iOnctura, a clinical stage biotechnology company developing breakthrough…
Destiny Pharma – Landmark XF-73 Phase 2 data published in journal
Announces publication of XF-73 nasal gel Phase 2 data in leading…
Sequana Medical announces additional patents for DSR® in China and the United States
Ghent, Belgium – 22 March 2023 – Sequana Medical NV (Euronext…
iOnctura Announces Publication Of Pioneering Research Describing The Unique Biological Features Of Roginolisib
Preclinical Data On Roginolisib, An Oral First-In-Class Non-ATP…
Leucid Bio and Great Ormond Street Hospital enter commercial agreement at new gene therapy manufacturing centre
Agreement to manufacture Leucid Lead asset, LEU011 for the…
Five companies receive additional financial support through BioInnovation Institute’s Venture House program
BioInnovation Institute (BII), an international non-profit foundation…
Aldena Therapeutics Accelerates its Novel and Disruptive Approach to Immuno-Dermatology
Founded by Medicxi with Georgia Tech and UMass scientists,…
DelSiTech Awarded a Grant to Develop Controlled and Sustained Release Injectables for Prophylactic HIV Vaccine
Turku, Finland – March 15, 2023 – DelSiTech Ltd, a Finnish…
Synaffix Announces Expansion of ADC Collaboration with MacroGenics
MacroGenics adds up to four ADC programs
MacroGenics may…
Positive phase 2 data from Atrial Fibrillation clinical trial – primary endpoint met
First-in-class SK channel inhibition proof of mechanism achieved
First…
Teitur Trophics Raises EUR 28M in Series A Financing to Advance the Development and Treatment for Neurodegenerative Diseases
Financing co-led by Sunstone Life Science Ventures and…
Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon[®] in IgA Nephropathy
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm:…
BioInnovation Institute welcomes innovative mycoprotein meat project into Bio Studio program
BioInnovation Institute (BII), an international non-profit foundation…
Poolbeg Pharma plc: POLB 001 patent portfolio strengthened through granting of US patent
Key highlights
· Patent granted for use of certain…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York
